Abstract
There were strong evidences that NO has capital importance in the progressive vasodilatation that associates to the varied circulatory shock forms. The decreased systemic vascular resistance observed in irreversible hemorrhagic (hypovolemic) and septic shock may be due to the excess production of nitric oxide. Other forms of shock associated to anaphylaxis (anaphylactic shock, SIRS) and ischemia reperfusion injury (cardiogenic shock, organ transplants), may involve nitric oxide overproduction. In these situations, the nitric oxide-induced loss of vascular sensitivity to catecholamines and myocardial depression contributes to lethal hypotension. As NO vasodilatation is cyclic GMP - mediated, there were two therapeutical options: a) The unspecific NO synthesis inhibition by L-arginine analogs, iNOS-specific inhibition by corticoids and/or aminoguanidine and; b) Guanylyl cyclase inhibition by MB. As the NO synthesis inhibition is associated to tissue necrosis and adverse hemodynamic effects and its clinical use was associated with high mortality, the second option using MB is safer and more rational. The elaboration of this text was motivated to suggest the guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.
Keywords: Nitric oxide, shock, vasoplegia, cyclic GMP, MB
Current Drug Targets
Title: The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Volume: 7 Issue: 9
Author(s): P.R. B. Evora and F. Viaro
Affiliation:
Keywords: Nitric oxide, shock, vasoplegia, cyclic GMP, MB
Abstract: There were strong evidences that NO has capital importance in the progressive vasodilatation that associates to the varied circulatory shock forms. The decreased systemic vascular resistance observed in irreversible hemorrhagic (hypovolemic) and septic shock may be due to the excess production of nitric oxide. Other forms of shock associated to anaphylaxis (anaphylactic shock, SIRS) and ischemia reperfusion injury (cardiogenic shock, organ transplants), may involve nitric oxide overproduction. In these situations, the nitric oxide-induced loss of vascular sensitivity to catecholamines and myocardial depression contributes to lethal hypotension. As NO vasodilatation is cyclic GMP - mediated, there were two therapeutical options: a) The unspecific NO synthesis inhibition by L-arginine analogs, iNOS-specific inhibition by corticoids and/or aminoguanidine and; b) Guanylyl cyclase inhibition by MB. As the NO synthesis inhibition is associated to tissue necrosis and adverse hemodynamic effects and its clinical use was associated with high mortality, the second option using MB is safer and more rational. The elaboration of this text was motivated to suggest the guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.
Export Options
About this article
Cite this article as:
Evora B. P.R. and Viaro F., The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226679
DOI https://dx.doi.org/10.2174/138945006778226679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Hypotensive Peptides from Snake Venoms: Structure, Function and Mechanism
Current Topics in Medicinal Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Biological Implications of Oxidation and Unidirectional Chiral Inversion of D-amino Acids
Current Drug Metabolism Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Biosafety of Adenoviral Vectors
Current Gene Therapy Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology The Role of Neuropeptide Processing Enzymes in Endocrine (Prostate) Cancer: EC 3.4.24.15 (EP24.15)
Protein & Peptide Letters Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Novel Strategies in the Treatment of Pulmonary Arterial Hypertension
Current Drug Targets